B+
Bull case
0%
Probability
Target price
$50.00
Analysis reference price unavailable
Analysis 2026-05-08 · RankAlpha Sentiment Codex
BRKR
BrukerDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
The checked post-earnings evidence supports only a cautious bull case: Bruker beat the Zacks-tracked Q1 consensus on both adjusted EPS ($0.31 vs $0.23) and revenue ($823.4 million vs $800.1 million), while management reaffirmed full-year revenue and EPS guidance and pointed to high-single-digit BSI organic bookings with book-to-bill above 1.0x for a third straight quarter.
Posture
Defensive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta -0.1.
What can break
Bruker reported total outstanding debt of about $1.7 billion as of March 31, 2026, limiting room for a more aggressive bullish stance until revenue conversion improves [#10-Q-2026-05-07].
Momentum
69
Value
57
Sentiment
29
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $45.00 · Bull $50.00 · Bear $39.00Analysis 2026-05-08; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-26 • Vendor: Data Vendor v1
Scores
As of 2026-10-26 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-08 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-26
Investment thesis
As of 2026-10-26
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-26. Definitions
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $63.83
Why
Momentum69 · Δ7d -15.6
Value57 · Δ7d -0.1
Sentiment29 · Δ7d -5.0
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Confirming evidence
- • Value remains the lead driver in the composite, 7D delta -0.1.
Contradictions & invalidation
- • Bruker reported total outstanding debt of about $1.7 billion as of March 31, 2026, limiting room for a more aggressive bullish stance until revenue conversion improves [#10-Q-2026-05-07].
- • Cash and cash equivalents fell to $133.4 million from $298.8 million at year-end, while inventories increased to $1.12 billion from $1.09 billion, which keeps working-capital execution in focus [#10-Q-2026-05-07].
- • The bear case remains more operationally grounded than valuation-driven: organic revenue was down 4.4%, non-GAAP operating income and margin both declined year over year, Q1 non-GAAP EPS fell from $0.47 to $0.31, and management still flagged U.S.
Catalyst clock
2026-08-06
Q2 organic-growth rebound is the key validation event
Lead driver: Value · See fundamentals
Momentum
69
8% active weight
Current posture
7d trendSoftening
Δ7d
-15.6
Δ21d
-10.1
Value
57
47% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
-0.6
Sentiment
29
45% active weight
Current posture
7d trendSoftening
Δ7d
-5.0
Δ21d
+3.3
Why this grade
Composite grade D. Momentum 69.5 / Value 57.3 / Sentiment 29.5
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-05-08. Scenario method
Most likely
B
Base case
1%
Probability
Target price
$45.00
Analysis reference price unavailable
Analysis 2026-05-08 · RankAlpha Sentiment Codex
B-
Bear case
0%
Probability
Target price
$39.00
Analysis reference price unavailable
Analysis 2026-05-08 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-26
Fundamentals (TTM)
As of 2026-10-26
Market Cap
$8.87B
Beta
1.18
Shares Out
152.36M
P/E (TTM)
184.1
P/S (TTM)
2.26
P/FCF (TTM)
346.07
Rev YoY
+5.2%
EPS YoY
-924.4%
Gross Margin
+47.3%
Op Margin
+8.5%
Net Debt
$1.74B
Current Ratio
1.85
As of 2026-10-26 • Updated nightlySource: Internal modelMethods & Data